晚期缓解不影响炎症性肠病1年结局
这项前瞻性单中心研究纳入596例中重度CD或UC患者,启动生物制剂或小分子药物后随访1年。约14%为晚期缓解者(14-30周达缓解),其52周临床和內镜缓解率与早期缓解者相当,且显著优于未缓解者。
要点
- 约六分之一患者在第30周实现延迟缓解。
- 晚期缓解者1年结局与早期缓解者相当。
- 识别延迟缓解预测因素可避免过早停药。
核心结论
- 晚期缓解者(14-30周达缓解)与早期缓解者相比,52周临床和內镜缓解率相似,且显著优于未缓解者。
研究设计与样本
- 前瞻性单中心研究,纳入596例中重度CD或UC患者,启动生物制剂或小分子药物,随访1年。
主要发现
- 第14周临床缓解率为37%,另有14%在14-30周实现缓解(晚期缓解者)。
- 晚期缓解者52周临床缓解率64% vs 早期63%,內镜缓解率43% vs 49%。
- 未缓解者52周临床和內镜缓解率分别为13%和16%,与晚期缓解者相比P<0.001。
- 晚期缓解者疾病病程略短,但人口学和疾病特征与早期缓解者相当。
关键数值与推荐
- 临床缓解定义:CD为Harvey-Bradshaw指数≤4,UC为Simple Clinical Colitis Activity Index≤2。
- 早期缓解:第14周达临床缓解;晚期缓解:第14周未缓解但第30周达缓解;未缓解:第30周仍未缓解。
临床怎么用
- 对于第14周未达缓解的患者,不应过早停药,可继续治疗至第30周评估延迟缓解可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In randomized trials, early improvement with biologic therapy in Crohn's disease (CD) and ulcerative colitis (UC) is linked to better long-term outcomes. However, some patients may respond later (late remitters). The frequency of such late remitters, predictors of who may belong to this group, and the long-term outcome of such patients have not been examined robustly. METHODS: This prospective single-center study enrolled patients with moderate-to-severe CD or UC initiating biologic or small molecule therapy. Disease activity was assessed prospectively using Harvey Bradshaw Index (CD) and Simple Clinical Colitis Activity Index (UC). Patients were followed for 1 year. Early remitters achieved clinical remission (Harvey-Bradshaw Index ≤4, Simple Clinical Colitis Activity Index ≤2) by week 14. Late remitters did not achieve remission by week 14 but attained remission by week 30. Nonremitters failed to achieve remission by week 30. RESULTS: Our cohort included 596 patients (280 CD, 316 UC) initiating anti-tumor necrosis factor (n = 174), vedolizumab (n = 171), anti-interleukin (primarily ustekinumab, n = 116), or Janus kinase inhibitors (primarily tofacitinib, n = 135). Most (89%) had previous biologic exposure. Clinical remission at week 14 occurred in 37%; an additional 14% achieved remission between weeks 14 and 30 (late remitters). Late remitters had slightly shorter disease duration but comparable demographics and disease characteristics to early responders. Late remitters had similar rates of clinical (64% vs 63%) and endoscopic remission (43% vs 49%) at week 52 compared with early remitters, with superior outcomes compared with nonremitters (13% and 16%, respectively; P < 0.001). DISCUSSION: Approximately one-sixth of patients achieved delayed remission by week 30. They had comparable 1-year outcomes as early remitters. Identifying predictors of delayed remission could help prevent early therapy discontinuation without affecting long-term outcomes.
引用
- Ghoneim S, Choe H, Boneschansker L, et al. Delayed Remission With Advanced Therapies Is Not Associated With Worse 1-Year Outcomes in Inflammatory Bowel Disease. Am J Gastroenterol. 2025. PMID: 41081564. doi:10.14309/ajg.0000000000003795
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。